Compare United States Copper Index Fund (CPER) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Summit Therapeutics Inc — how do they compare? United States Copper Index Fund trades at $38.33, while Summit Therapeutics Inc trades at $15.64 (market cap $12.01B). The key difference: United States Copper Index Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CPER | SMMT | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $40.60 | $29.32 |
52-Week Low | $27.21 | $13.05 |
Market Cap | — | $12.01B |
Enterprise Value | — | $11.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER, the United States Copper Index Fund, trades at $37.94, down 0.13% on the day, with a bullish technical signal driven by moving averages. Recent news highlights copper's strong performance tied to AI and electrification demand, with articles from 24/7 Wall Street and Reuters in July 2026 noting copper's 33% annual gain and structural demand drivers. Key support and resistance cluster around $38.
The outlook for CPER remains positive given copper's fundamental role in energy transition and AI infrastructure, though risks include potential global manufacturing weakness and substitution threats from aluminum. Investor sentiment is buoyant, but price sensitivity to macroeconomic trends warrants caution.
Summit Therapeutics (SMMT) trades at $15.30, showing modest daily gains of 0.33%. The stock faces bearish technical signals with negative cash flows and substantial losses (-$1.08B net income in 2025). Recent developments include the sale of Phase III asset ridinilazole and positive clinical trial results for ivonescimab. Analyst sentiment remains optimistic with 67% buy ratings and a $15.57 consensus target, though financial metrics show concerning profitability with -270.95% ROE.
SMMT presents a high-risk, catalyst-driven opportunity with binary outcomes dependent on clinical success. The company's heavy reliance on ivonescimab development creates significant upside potential but also substantial execution risk. Negative cash flow trends and persistent losses require careful monitoring of upcoming Q2 2026 earnings and clinical milestones for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
